Seema Verma asked taxpayers to reimburse $43K of stolen jewelry

CMS Administrator Seema Verma asked taxpayers to reimburse $47,000 worth of property that was stolen while she was in San Francisco for a speech. The claims include about $43,000 for two dozen pieces of jewelry, including a $5,900 pendant from the Ivanka Trump brand, Politico reported Dec. 7. Her property and jewelry were not insured.

Ultimately, Verma was reimbursed for nearly $3,000 of her lost property. The claim also included $325 for moisturizer and $349 for noise-cancelling headphones, Politico reported. Verma was partially reimbursed because HHS covers certain goods when they are lost during a work trip. However, HHS cannot reimburse for items like jewelry.

The report prompted at least one Congressman, Rep. Joe Kennedy (D-Mass.) to call on Verma to resign over a “gross misuse of public funds.” Kennedy previously grilled Verma during a congressional hearing earlier this year over $2 million in contracted public relations services, some of which was directed to promote Verma.

The jewelry controversy also comes at a time when Verma has faced other challenges, including a fraught relationship with HHS Secretary Alex Azar that has gained attention.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.